AstraZeneca (NASDAQ:AZN) is trading down 0.26% at 8129.00 Britain’s competition regulator is reviewing AstraZeneca (NASDAQ:AZN)’s $39 billion buyout of U.S.-based Alexion (NASDAQ:ALXN) on concerns it could reduce competition in the
Read More
.